Therapeutic antibodies against CGRP or its receptor

British Journal of Clinical Pharmacology

Volumn 79, Issue 6, 2015, Pages 886-895

  Bigal, Marcelo E ^a,b   Walter, Sarah ^c   Rapoport, Alan M ^d,e  

^a Vice Pres Migraine and Headache Clinical Development Teva Pharmaceuticals   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c TEVA PHARMACEUTICALS   (Israel)

^d NEW ENGLAND CENTER FOR HEADACHE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CGRP; chronic migraine; migraine; monoclonal antibodies

Indexed keywords

ALD 403; AMG 334; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; LY 2951742; MONOCLONAL ANTIBODY; PLACEBO; TEV 48125; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; BACKACHE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; EPISODIC MIGRAINE; FATIGUE; HEADACHE; HUMAN; INJECTION SITE REACTION; MIGRAINE; NAUSEA AND VOMITING; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TRANSFORMED MIGRAINE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIGRAINE DISORDERS; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CALCITONIN GENE-RELATED PEPTIDE; DRUG DISCOVERY; HUMANS; MIGRAINE DISORDERS; MOLECULAR TARGETED THERAPY; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84929345915     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12591     Document Type: Article

References (77)

1. Goadsby PJ, Lipton RB, Ferrari MD,. Migraine - current understanding and treatment. N Engl J Med. 2002; 346: 257-70.
2. Headache Classification Subcommittee of the International Headache S. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 (Suppl 1): 9-160.
3. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF,. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885-94.
4. Bigal ME, Serrano D, Reed M, Lipton RB,. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559-66.
5. Di Clemente L, Coppola G, Magis D, Fumal A, De Pasqua V, Di Piero V, Schoenen J,. Interictal habituation deficit of the nociceptive blink reflex: an endophenotypic marker for presymptomatic migraine? Brain 2007; 130: 765-70.
6. Coppola G, Vandenheede M, Di Clemente L, Ambrosini A, Fumal A, De Pasqua V, Schoenen J,. Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. Brain 2005; 128: 98-103.
7. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SMA, Picavet HSJ, Launer LJ,. The impact of migraine on quality of life in the general population. The GEM Study. Neurology 2000; 55: 624-9.
8. Lipton RB, Hemelsky SW, Kolodner KN, Steiner TJ, Stewart WF,. Migraine, quality of life and depression. A population-based case-control study. Neurology 2000; 55: 629-35.
9. Bigal ME, Lipton RB,. Clinical course in migraine: conceptualizing migraine transformation. Neurology 2008; 71: 848-55.
10. Lance JW, Goadsby PJ,. Mechanism and Management of Headache. 7th ed. New York: Elsevier, 2005.
11. Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ,. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 2009; 49 (Suppl 1): S21-33.
12. Hargreaves RJ,. 10 years of rizatriptan. Headache 2009; 49 (Suppl 1): S1-2.
13. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB,. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 2013; 53: 644-55.
14. Edvinsson L, Chan KY, Eftekhari S, Nilsson E, de Vries R, Saveland H, Dirven CM, Danser AH, MaassenVanDenBrink A,. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 2010; 30: 1233-40.
15. Edvinsson L, Petersen KA,. CGRP-receptor antagonism in migraine treatment. CNS Neurol Disord Drug Targets. 2007; 6: 240-6.
16. Storer RJ, Akerman S, Goadsby PJ,. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004; 142: 1171-81.
17. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J,. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54-61.
18. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK,. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115-23.
19. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW,. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31: 712-22.
20. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, Group BBCPoCS. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-10.
21. Silberstein SD,. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013; 93: 78-85.
22. Hoffmann J, Goadsby PJ,. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol 2012; 14: 50-9.
23. Akerman S, Holland PR, Goadsby PJ,. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011; 12: 570-84.
24. Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS, Goadsby PJ,. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain J Neurology 2005; 128: 932-9.
25. Moskowitz MA,. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43 (Suppl 3): S16-20.
26. Moskowitz MA, Cutrer FM,. CGRP: blood flow and more? Cephalalgia 1996; 16: 287.
27. Kilo S, Harding-Rose C, Hargreaves KM, Flores CM,. Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin. Pain 1997; 73: 201-7.
28. Edmeads J,. What is migraine? Controversy and stalemate in migraine pathophysiology. J Neurol 1991; 238 (Suppl 1): S2-5.
29. Lauritzen M., Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994; 117: 199-210.
30. Leao AA,. The slow voltage variation of cortical spreading depression of activity. Electroencephalogr Clin Neurophysiol 1951; 3: 315-21.
31. Leao AA,. Further observations on the spreading depression of activity in the cerebral cortex. J Neurophysiol 1947; 10: 409-14.
32. Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ,. Brainstem activation specific to migraine headache. Lancet 2001; 357: 1016-7.
33. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC,. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-60.
34. Afridi S, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RSJ, Goadsby PJ,. A PET study in spontaneous migraine. Arch Neurol 2005; 62: 1270-5.
35. Haas DC, Kent PF, Friedman DI,. Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache 1993; 33: 452-5.
36. Goadsby PJ,. Neurovascular headache and a midbrain vascular malformation- evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002; 22: 107-11.
37. Afridi S, Goadsby PJ,. New onset migraine with a brainstem cavernous angioma. J Neurol Neurosurg Psychiatry 2003; 74: 680-2.
38. Obermann M, Gizewski ER, Limmroth V, Diener H-C, Katsarava Z,. Symptomatic migraine and pontine vascular malformation: evidence for a key role of the brainstem in the pathophysiology of chronic migraine. Cephalalgia 2006; 26: 763-6.
39. Moskowitz MA, Nozaki K, Kraig RP,. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993; 13: 1167-77.
40. Goadsby PJ, Edvinsson L, Ekman R,. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193-6.
41. Goadsby PJ,. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 2005; 65: 2557-67.
42. Edvinsson L, Jansen Olesen I, Kingman TA, McCulloch J, Uddman R,. Modification of vasoconstrictor responses in cerebral blood vessels by lesioning of the trigeminal nerve: possible involvement of CGRP. Cephalalgia Int J headache 1995; 15: 373-83.
43. Troltzsch M, Denekas T, Messlinger K,. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 2007; 562: 103-10.
44. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L,. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain Official J Am Pain Soc 2013; 14: 1289-303.
45. Markowitz S, Saito K, Buzzi MG, Moskowitz MA,. The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells. Brain Res 1989; 477: 157-65.
46. Benarroch EE,. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 2011; 77: 281-7.
47. Edvinsson L, Linde M,. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010; 376: 645-55.
48. Bigal ME, Walter S, Rapoport AM,. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 2013; 53: 1230-44.
49. Pettypiece S,. Merck halts testing of migraine drug on liver safety (Update2) 2009 [04/04/2013]. Available from: http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aKxzpNBZ2cbA.
50. Cholerton M,. The hypothalamus in migraine. Optician 1948; 116: 275-7.
51. Durham PL,. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache 2008; 48: 1269-75.
52. Durham PL, Masterson CG,. Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache 2013; 53: 67-80.
53. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF,. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci 2009; 29: 8798-804.
54. Bigal ME, Walter S,. Monoclonal antibodies for migraine: Preventing calcitonin gene-related peptide Activity. CNS Drugs 2014; 28: 389-99.
55. Baumann A., Early development of therapeutic biologics - pharmacokinetics. Curr Drug Metab 2006; 7: 15-21.
56. Tfelt-Hansen PC,. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2013; 80: 869-70.
57. Berton E,. Safety pharmacology: similarities and differences between small molecules and novel biotherapeutics. In: Preclinical safety evaluation of biopharmaceuticals, ed., Cavagnaro J, New York, NY: Wiley, 2008.
58. Young S,. Preventing migraines with a new kind of antibody http://medcitynews.com/2013/05/preventing-migraines-with-a-new-kind-of-antibody/2013 [cited 2013 10/08/2013]. Available from: http://medcitynews.com/2013/05/preventing-migraines-with-a-new-kind-of-antibody/.
59. Alder BioPharmaceuticals I. Form S-1 Registration statement, under the Securities Act of 1933 http://www.sec.gov/Archives/edgar/data/1423824/000119312514104868/d657876ds1.htm2014 [cited 2014 09/01/2014]. Available from: http://www.sec.gov/Archives/edgar/data/1423824/000119312514104868/d657876ds1.htm.
60. Alder Biopharmaceuticals I. Safety Tolerability and Pharmacokinetics of ALD403: Alder Biopharmaceuticals, Inc. Available from: http://clinicaltrial.gov/ct2/show/NCT01579383?term=ALD403&rank=1.
61. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, investigators ALDs. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014; 13: 1100-7.
62. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of N, the American Headache S. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337-45.
63. Amgen-Science-Pipeline, 2013 [cited 2013 04/10]. Available from: http://www.amgen.com/science/pipe.html.
64. Ascending Single Doses of AMG 334 in healthy subjects and migraine patients, 2013 [cited 2013 04/10]. Available from: http://clinicaltrial.gov/ct2/show/NCT01688739?term=AMG334&rank=1.
65. Ascending multiple-doses of AMG 334 in healthy subjects and in migraine patients, 2013 [cited 2013 04/10]. Available from: http://clinicaltrial.gov/ct2/show/NCT01723514?term=AMG334&rank=2.
66. Amgen. A phase 2 study to evaluate the efficacy and safety of AMG 334 in migraine prevention: clinicaltrial.gov, 2013 [cited 2014 01/18/2014]. Available from: http://clinicaltrial.gov/ct2/show/NCT01952574?term=AMG+334&rank=4.
67. Amgen. A study to evaluate the efficacy and safety of AMG 334 in chronic migraine prevention, 2014 [cited 2014 09/01/2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02066415?term=AMG334&rank=6.
68. Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention, 2014 [cited 2014 09/01/2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02174861?term=AMG334&rank=5.
69. Anderson P,. Monoclonal antibodies promising for migraine prevention: Medscape, 2014 [cited 2014 09/01/2014]. Available from: http://www.medscape.com/viewarticle/827838.
70. de Hoon J, Montieth D, Vermeersch S, Van Hecken A, Abu-Raddad E, Collins E, Schuetz T, Scherer J, Grayzel D,. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: A monoclonal antibody targeting CGRP. Cephalalgia 2013. Available from: http://cep.sagepub.com/content/33/8-suppl/1.full.pdf+html.
71. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS,. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurology 2014; 13: 885-92.
72. Company ELa. A study of LY2951742 in participants with migraine headache, 2014 [cited 2014 09/01/2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02163993?term=LY2951742&rank=1.
73. Walter S, Alibhoy A, Escandon R, Bigal ME,. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014; 6: 871-8.
74. Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P,. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia 2013; 34: 483-92.
75. Bigal ME, Walter S,. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014; 28: 389-99.
76. Bigal ME, Walter S, Bronson M, Alibhoy A, Sager P, Escandon R,. Cardiovascular and Hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014; 34: 968-76.
77. Koehler PJ, Tfelt-Hansen PC,. History of methysergide in migraine. Cephalalgia 2008; 28: 1126-35.